Citations

Showing 10 of 108152 citations.

Gender Differences in Compensation in Anesthesiology in the United States: Results of a National Survey of Anesthesiologists
Hertzberg, Linda B., Miller, Thomas R. , Byerly, Stephanie I., Rebello, Elizabeth , Flood, Pamela , Malinzak, Elizabeth B. , Doyle, Christine , Pease, Sonya, Rock-Klotz, Jennifer , Kraus, Molly B. , Pai, Sher‐Lu , Pai, Sher-Lu , Kraus, Molly B , Pease, Sonya

Mayo Clinic

Anesthesia & Analgesia | August 10, 2021 | Volume: 133 | Issue: 4 | Pages: 1009-1018

10.1213/ane.0000000000005676 | PMID 34375316 Get It

BACKGROUND: A gender-based compensation gap among physicians is well documented. Even after adjusting for age, experience, work hours, productivity, and academic rank, the gender gap remained and widened over the course of a physician’s career. This study aimed to examine if a significant gender pay gap still existed for anesthesiologists in the United States. METHODS: In 2018, we surveyed 28,812 physician members of the American Society of Anesthesiologists to assess the association of compensation with gender and to identify possible causes of wage disparities. Gender was the primary variable examined in the model, and compensation by gender was the primary outcome. Compensation was defined as the amount reported as direct compensation on a W-2, 1099, or K-1, plus all voluntary salary reductions (eg, 401[k], health insurance). The survey directed respondents to include salary, bonuses, incentive payments, research stipends, honoraria, and distribution of profits to employees. Respondents had the option of providing a point estimate of their compensation or selecting a range in $50,000 increments. Potential confounding variables that could affect compensation were identified based on a scoping literature review and the consensus expertise of the authors. We fitted a generalized ordinal logistic regression with 7 ranges of compensation. For the sensitivity analyses, we used linear regressions of log-transformed compensation based on respondent point estimates and imputed values. RESULTS: The final analytic sample consisted of 2081 observations (response rate, 7.2%). This sample represented a higher percentage of women and younger physicians compared to the demographic makeup of anesthesiologists in the United States. The adjusted odds ratio associated with gender equal to woman was an estimated 0.44 (95% confidence interval, 0.37–0.53), indicating that for a given compensation range, women had a 56% lower odds than men of being in a higher compensation range. Sensitivity analyses found the relative percentage difference in compensation for women compared to men ranged from −8.3 to −8.9. In the sensitivity analysis based on the subset of respondents (n = 1036) who provided a point estimate of compensation, the relative percentage difference (−8.3%; 95% confidence interval, −4.7 to −11.7) reflected a $32,617 lower compensation for women than men, holding other covariates at their means. CONCLUSIONS: Compensation for anesthesiologists showed a significant pay gap that was associated with gender even after adjusting for potential confounding factors, including age, hours worked, geographic practice region, practice type, position, and job selection criteria.
Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia
Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Shih, Angela, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., VanderLaan, Paul A., Berigei, Sarita R., Mino-Kenudson, Mari, Horick, Nora K., Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Horick, Nora , Liang, Lloyd L. , VanderLaan, Paul A. , Shih, Angela , Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., Berigei, Sarita R., Mino-Kenudson, Mari, Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Shih, Angela , Horick, Nora

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 10, 2021 | Volume: 204 | Issue: 10 | Pages: 1164-1179

10.1164/rccm.202104-0847oc | PMID 34375171 Get It

Abstract Rationale Early, accurate diagnosis of interstitial lung disease (ILD) informs prognosis and therapy, especially in idiopathic pulmonary fibrosis (IPF). Current diagnostic methods are imperfect. High-resolution computed tomography has limited resolution, and surgical lung biopsy (SLB) carries risks of morbidity and mortality. Endobronchial optical coherence tomography (EB-OCT) is a low-risk, bronchoscope-compatible modality that images large lung volumes in vivo with microscopic resolution, including subpleural lung, and has the potential to improve the diagnostic accuracy of bronchoscopy for ILD diagnosis. Objectives We performed a prospective diagnostic accuracy study of EB-OCT in patients with ILD with a low-confidence diagnosis undergoing SLB. The primary endpoints were EB-OCT sensitivity/specificity for diagnosis of the histopathologic pattern of usual interstitial pneumonia (UIP) and clinical IPF. The secondary endpoint was agreement between EB-OCT and SLB for diagnosis of the ILD fibrosis pattern. Methods EB-OCT was performed immediately before SLB. The resulting EB-OCT images and histopathology were interpreted by blinded, independent pathologists. Clinical diagnosis was obtained from the treating pulmonologists after SLB, blinded to EB-OCT. Measurements and Main Results We enrolled 31 patients, and 4 were excluded because of inconclusive histopathology or lack of EB-OCT data. Twenty-seven patients were included in the analysis (16 men, average age: 65.0 yr): 12 were diagnosed with UIP and 15 with non-UIP ILD. Average FVC and Dl CO were 75.3% (SD, 18.5) and 53.5% (SD, 16.4), respectively. Sensitivity and specificity of EB-OCT was 100% (95% confidence interval, 75.8–100.0%) and 100% (79.6–100%), respectively, for both histopathologic UIP and clinical diagnosis of IPF. There was high agreement between EB-OCT and histopathology for diagnosis of ILD fibrosis pattern (weighted κ: 0.87 [0.72–1.0]). Conclusions EB-OCT is a safe, accurate method for microscopic ILD diagnosis, as a complement to high-resolution computed tomography and an alternative to SLB.
Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era
Verdoorn, Brandon P. , Evans, Tamara K., Hanson, Gregory J. , Zhu, Yi , Prata, Larissa , Pignolo, Robert J. , Atkinson, Elizabeth J. , Wissler-Gerdes, Erin O., Kuchel, George A. , Mannick, Joan B. , Rizza, Stacey A. , Musi, Nicolas , Lipsitz, Lewis A. , Yung, Raymond , McCarthy, Teresa , Puskarich, Michael A. , Niedernhofer, Laura J. , Kirkland, James L. , Gerdes, Erin O. Wissler , Langhi Prata, Larissa G P, Sorenson, Matthew, Tchkonia, Tamara, Wissler Gerdes, Erin O , Prata, Larissa G P Langhi , Niedernhofer, Laura J , Kuchel, George A , Zhu, Yi , Hanson, Gregory J., Kritchevsky, Stephen B. , Khosla, Sundeep , Walston, Jeremy D , Kiel, Douglas P. , LeBrasseur, Nathan K. , Singh, Ravinder J. , Robbins, Paul D. , Sorenson, Matthew , Tchkonia, Tamar

Mayo Clinic

Journal of the American Geriatrics Society | August 10, 2021 | Volume: 69 | Issue: 11 | Pages: 3023-3033

10.1111/jgs.17416 | PMID 34375437 Get It

Abstract The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS‐CoV‐2 infection. SARS‐CoV‐2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence‐associated secretory phenotype (SASP). The SASP can be amplified by infection‐related pathogen‐associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS‐CoV‐2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS‐CoV‐2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health‐funded, multicenter, placebo‐controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS‐CoV‐2 rtPCR‐positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long‐term care settings in the SARS‐CoV‐2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials.
Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation
Warlick, Erica D. , Üstün, Celalettin , Andreescu, Astrid C. M., Bonagura, Anthony, Brunner, Andrew M. , Foran, James M. , Kindwall‐Keller, Tamila L. , Klimek, Virginia M., Pease, Daniel F. , Waldman, Bryce, Horowitz, Mary M. , Burns, Linda J. , Khera, Nandita , Foran, James M , Khera, Nandita , Chandra, Abhinav Binod , Juckett, Mark , Steensma, David P.

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 23 | Pages: 4339-4347

10.1002/cncr.33826 | PMID 34375439 Get It

Lay Summary People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under‐represented racial and ethnic backgrounds.
Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China
Tian, Panwen , Qiu, Rong , Xu, Shufeng , Wang, Meifang , Cao, Liming , Yang, Ping , Li, Weimin

Mayo Clinic

JAMA Network Open | August 10, 2021 | Volume: 4 | Issue: 8 | Pages: e2120306

10.1001/jamanetworkopen.2021.20306 | PMID 34374774 Get It

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older
Munshi, Pashna N. , Vesole, David H. , Martin, Andrew St., Dávila, Omar, Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , D’Souza, Anita , Qazilbash, Muzaffar H , D'Souza, Anita , Hari, Parameswaran

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 22 | Pages: 4233-4239

10.1002/cncr.33831 | PMID 34374445 Get It

BackgroundConsolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old.MethodsPatients with MM ≥75 years old receiving AHCT between 2013 and 2017 in the United States were identified using the Center for International Blood and Marrow Transplant Research database. Relapse and/or progression (REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. Covariates used were age, sex, Karnofsky performance score (KPS), HCT‐comorbidity index (HCT‐CI), International Staging System and/or Durie‐Salmon stage, high‐risk cytogenetics, melphalan dose, and disease status at and 1 year after transplant. AHCT utilization rate using the Surveillance, Epidemiology, and End Results database was used to estimate specific incidence among ≥75 years old by race and gender.ResultsOf 360 patients, 63% were male, 84% were White, 56% had KPS <90, and 57% had HCT‐CI ≥3. The 100‐day transplant‐related mortality was 1% (0%‐2%) with a 2‐year REL rate of 27% (95% confidence interval [CI], 22%‐33%), PFS of 66% (95% CI, 60%‐72%), and OS of 83% (95% CI, 78%‐87%). On multivariate analysis, only high‐risk cytogenetics was associated with REL risk and decreased PFS. In White males, transplant utilization rate was 5.2%‐5.8% compared to 3.5%‐4.0% in African American males (P = .02). There was 3.37‐3.79% transplant utilization in White females compared to 1.88‐2.12% in African American females (P < .01).ConclusionsThe use of AHCT was associated with excellent 2‐year outcomes in this selected MM population ≥75 years old. Transplant utilization for patients ≥75 years old remains low with significant racial and gender disparities.
Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)
Snyder, Rebecca A. , Le‐Rademacher, Jennifer , Dodge, Andrew , Chang, George J. , Innocenti, Federico , Blanke, Charles D. , Lenz, Heinz‐Josef, Polite, Blasé N. , Le-Rademacher, Jennifer G , Zemla, Tyler J, Polite, Blasé N , He, Jun , Ou, Fang‐Shu , Zemla, Tyler , Paskett, Electra D. , Lenz, Heinz‐Josef , Venook, Alan P. , Snyder, Rebecca A

Mayo Clinic

Cancer | August 10, 2021 | Volume: 127 | Issue: 20 | Pages: 3801-3808

10.1002/cncr.33649 | PMID 34374082 Get It

BackgroundThe objective of this study was to evaluate the association between self‐identified race and overall survival (OS), progression‐free survival (PFS), and response to therapy among patients enrolled in the randomized Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.MethodsPatients with advanced or metastatic colorectal cancer who were enrolled in the CALGB/SWOG 80405 trial were identified by race. On the basis of covariates (treatment arm, KRAS status, sex, age, and body mass index), each Black patient was exact matched with a White patient. The association between race and OS and PFS was examined using a marginal Cox proportional hazard model for matched pairs. The interaction between KRAS status and race was tested in the model. The association between race and response to therapy and adverse events were examined using a marginal logistic regression model.ResultsIn total, 392 patients were matched and included in the final data set. No difference in OS (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.73‐1.16), PFS (HR, 0.97; 95% CI, 0.78‐1.20), or response to therapy (odds ratio [OR], 1.00; 95% CI, 0.65‐1.52) was observed between Black and White patients. Patients with KRAS mutant status (HR, 1.31; 95% CI, 1.02‐1.67), a performance statusscore of 1 (reference, a performance status of 0; HR, 1.49; 95% CI, 1.18‐1.88), or ≥3 metastatic sites (reference, 1 metastatic site; HR, 1.67; 95% CI, 1.22‐2.28) experienced worse OS. Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24‐0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72‐1.65).ConclusionsNo difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.Lay Summary Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer. The purpose of this study was to determine whether there was a difference in cancer‐specific outcomes among Black and White patients receiving equivalent treatment on the CALGB/SWOG 80405 randomized clinical trial. In this study, there was no difference in overall survival, progression‐free survival, or response to therapy between Black and White patients treated on a clinical trial. These findings suggest that access to care and differences in treatment may be responsible for racial disparities in colorectal cancer.
High Return to Play Rate and Reduced Career Longevity Following Surgical Management of Athletic Pubalgia in National Basketball Association Players
Castle, Joshua , Kessler, Adam , Wager, Susan , Khalil, Lafi S. , Okoroha, Kelechi R. , Mehran, Nima , Abbas, Muhammad J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | August 10, 2021 | Volume: 3 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2021.07.001 | PMID 34712974 Get It

Purpose To assess the effects of surgical treatment of athletic pubalgia (AP) on game use and performance metrics in National Basketball Association (NBA) players. Methods A retrospective review of all NBA players who underwent surgical management for AP from 1996 to 2018 was performed. A matched control group was created for comparison. The index period was defined as the entire NBA season in which surgery occurred, including the corresponding offseason. Player demographics, use (games played, games started, and minutes per game) and performance (player efficiency rating) metrics were collected for all players. Statistical analysis was performed to compare data before and after return to play. Results Thirty players with a history of surgical management for AP were included in the final analysis. Following surgery for AP, NBA players were found to have a return to play (RTP) rate of 90.91% (30/33). The average RTP following surgery was 4.73 ± 2.62 months. Compared with control athletes, athletes in the AP group played significantly fewer seasons postinjury (4.17 ± 2.70 vs 5.49 ± 3.04 seasons, respectively; P = .02). During the first year following RTP, NBA players experienced significant reductions in game use and performance, both when compared with the year prior and matched control athletes ( P < .05). At 3‐year follow‐up, players continued to demonstrate significant reductions in game use (minutes per game, P < .05) but not performance. Conclusions Following surgical treatment of AP, NBA players demonstrated a high RTP rate, but shortened career. A short‐term reduction in game use and performance metrics was found the year of return following surgery. However, 3‐year follow‐up performance metrics normalized when compared with healthy controls. Study Design Level III; retrospective case‐control study.
Evaluating the potential cost savings from inpatient dermatology consultations
Puri, Pranav , Wiggins, M , Yousif, Muneera, Pollock, Benjamin D. , Fox, Lindy P., Rosenbach, Misha , Pittelkow, Mark R. , Mangold, Aaron R. , Puri, P , Mangold, A R , Pollock, Benjamin D , Yousif, M.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | August 10, 2021 | Volume: 35 | Issue: 12 | Pages: No page available

10.1111/jdv.17595 | PMID 34374133 Get It